Jiangsu Nhwa Pharmaceutical (002262) Q1 2025 earnings summary

Executive summary

• Revenue for Q1 2025 reached RMB 1.51 billion, up 11.29% year-over-year.

• Net profit attributable to shareholders was RMB 300.71 million, a 13.35% increase year-over-year.

• Operating cash flow rose 36.69% year-over-year to RMB 319.27 million.

• Growth driven by increased sales, higher investment income, and improved cash management.

Financial highlights

• Basic and diluted EPS were RMB 0.30, up from RMB 0.26 year-over-year.

• Total assets at quarter-end were RMB 8.87 billion, up 5.08% from year-end 2024.

• Shareholders' equity increased 4.37% to RMB 7.62 billion.

• Excluding non-recurring items, net profit rose 12.18% year-over-year.

• Investment income from short-term wealth management products increased 82.07% year-over-year.

Outlook and guidance

• Management expects continued benefit from increased R&D and sales investments.

• Ongoing focus on cash management and efficiency in capital utilization.